ShareValue scores for 300016.SHE: Valuation 56, Quality 54, Growth 78, Health 50.
300016.SHESZSE
Beijing Beilu Pharmaceutical
CN¥7.85
(+8.58%)
300016.SHESZSE
Beijing Beilu Pharmaceutical
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as well as iodine-based agents comprising iohexol, ioversol, iodixanol, iopromide, and iopamidol, as well as oral anti-diabetic drugs. The company was founded in 1992 and is based in Beijing, China.